Cited by 186Cancer-related Molecular PathwaysHeat shock proteins researchProtein Structure and Dynamics

The DOI matches its Crossref record; 103 of the 105 references it cites were found in a registry or an index.

Reactivation of mutant p53: molecular mechanisms and therapeutic potential

Selivanova, G, Wiman, K G·2007·Oncogene

Open this paper in CoChat — free account

Abstract

The p53 tumor suppressor gene is the most frequently mutated gene in cancer. Most p53 mutations are missense point mutations that cluster in the DNA-binding core domain. This results in distortion of core domain folding and disruption of DNA binding and transcriptional transactivation of p53 target genes. Structural studies have demonstrated that mutant p53 core domain unfolding is not irreversible. Mutant p53 is expressed at high levels in many tumors. Therefore, mutant p53 is a promising target for novel cancer therapy. Mutant p53 reactivation will restore p53-dependent apoptosis, resulting in efficient removal of tumor cells. A number of strategies for targeting mutant p53 have been designed, including peptides and small molecules that restore the active conformation and DNA binding to mutant p53 and induce p53-dependent suppression of tumor cell growth in vitro and in vivo. This opens possibilities for the clinical application of mutant p53 reactivation in the treatment of cancer.

Integrity signals

Registry

Crossref · 10.1038/sj.onc.1210295

Cites

103 of 103 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Live or let die: the cell's response to p53
Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161
Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P. (1994) · Science · doi:10.1126/science.8023157 · Cited by 2,559 · cited 2×
“…more recent nuclear magnetic resonance (NMR) and X-ray studies on tumor-derived core domain mutants have revealed the structural impact of amino-acid residues that are most frequently mutated in human cancers (Cho et al., 1994; Wong et al., 1999; Joerger et al., 2004, 2005a, b; Ang et al., 2006).”
Background
The IARC TP53 database: new online mutation analysis and recommendations to users
Olivier, M., Eeles, R., Hollstein, M., Khan, M. A., Harris, C. C., & Hainaut, P. (2002) · Human Mutation · doi:10.1002/humu.10081 · Cited by 1,248
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Self-citation
Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form.
Gannon, J., Greaves, R. F., Iggo, R. D., & Lane, D. P. (1990) · The EMBO Journal · doi:10.1002/j.1460-2075.1990.tb08279.x · Cited by 970
The Rb/E2F pathway and cancer
Nevins, J. R. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.7.699 · Cited by 939
Pharmacological Rescue of Mutant p53 Conformation and Function
Foster, B. A., Coffey, H. A., Morin, M. J., & Rastinejad, F. (1999) · Science · doi:10.1126/science.286.5449.2507 · Cited by 802
Presence of a Potent Transcription Activating Sequence in the p53 Protein
Fields, S., & Jang, S. K. (1990) · Science · doi:10.1126/science.2144363 · Cited by 790
Differential induction of transcriptionally active p53 following UV or lonizing radiation: Defects in chromosome instability syndromes?
Lü, X. (1993) · Cell · doi:10.1016/0092-8674(93)90496-d · Cited by 773
Inhibiting the p53–MDM2 interaction: an important target for cancer therapy
Chène, P. (2003) · Nature Reviews Cancer · doi:10.1038/nrc991 · Cited by 765
ASPP Proteins Specifically Stimulate the Apoptotic Function of p53
Samuels-Lev, Y., O'Connor, D. J., Bergamaschi, D., Trigiante, G., Hsieh, J.-K., Zhong, S., Campargue, I., Naumovski, L., Crook, T., & Lu, X. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00367-7 · Cited by 664
Structure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2
Gorina, S. S., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.1001 · Cited by 575
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
Marín, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O’Nions, J., TIDY, J. A., James, N. D., McGregor, J., Harwood, C. A., Yuluğ, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 511
A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain
Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464
Transcriptional Regulation by p53 through Intrinsic DNA/Chromatin Binding and Site-Directed Cofactor Recruitment
Espinosa, J. M., & Emerson, B. M. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00283-0 · Cited by 440
Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy
Bullock, A. N., Henckel, J., & Fersht, A. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203434 · Cited by 440
Thermodynamic stability of wild-type and mutant p53 core domain
Bullock, A. N., Henckel, J., DeDecker, B. S., Johnson, C. M., Nikolova, P. V., Proctor, M. R., Lane, D. P., & Fersht, A. R. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.26.14338 · Cited by 405
The pathological response to DNA damage does not contribute to p53-mediated tumour suppression
Christophorou, M. A., Ringshausen, I., Finch, A. J., Swigart, L. B., & Evan, G. I. (2006) · Nature · doi:10.1038/nature05077 · Cited by 382
Structural basis for understanding oncogenic p53 mutations and designing rescue drugs
Joerger, A. C., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607286103 · Cited by 368
Cancer gene therapy: fringe or cutting edge?
McCormick, F. P. (2001) · Nature reviews. Cancer · doi:10.1038/35101008 · Cited by 345
Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain
Selivanova, G., Iotsova, V., Okan, İ., Fritsche, M., Ström, M., Groner, B., Grafström, R. C., & Wiman, K. G. (1997) · Nature Medicine · doi:10.1038/nm0697-632 · Cited by 341
Self-citation
Inhibitors of the HSP90 Molecular Chaperone: Current Status
Sharp, S. Y., & Workman, P. (2006) · Advances in cancer research · doi:10.1016/s0065-230x(06)95009-x · Cited by 312
Mutant conformation of p53 translated in vitro or in vivo requires functional HSP90.
Blagosklonny, M. V., Toretsky, J. A., Bohen, S. P., & Neckers, L. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8379 · Cited by 312
Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription
Chipuk, J. E., Maurer, U., Green, D. R., & Schüler, M. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00272-1 · Cited by 302
Allosteric activation of latent p53 tetramers
Hupp, T. R., & Lane, D. P. (1994) · Current Biology · doi:10.1016/s0960-9822(00)00195-0 · Cited by 300
Selenomethionine regulation of p53 by a ref1-dependent redox mechanism
Seo, Y. R., Kelley, M. R., & Smith, M. L. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212319799 · Cited by 284
p53 Contains Large Unstructured Regions in its Native State
Bell, S. J., Klein, C., Müller, L., Hansen, S., & Büchner, J. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00848-3 · Cited by 276
A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein.Preprint
Bargonetti, J., Manfredi, J. J., Chen, X., Marshak, D. R., & Prives, C. L. (1993) · Genes & Development · doi:10.1101/gad.7.12b.2565 · Cited by 271
A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants
Friedler, A., Hansson, L. O., Veprintsev, D. B., Freund, S. M. V., Rippin, T. M., Nikolova, P. V., Proctor, M. R., Rüdiger, S., & Fersht, A. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241629998 · Cited by 268
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
Self-citation
An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo
Midgley, C., Desterro, J. M. P., Saville, M. K., Howard, S. F., Sparks, A., Hay, R. T., & Lane, D. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203593 · Cited by 250
Reactivation of Mutant p53 and Induction of Apoptosis in Human Tumor Cells by Maleimide Analogs
Bykov, V. J. N., Issaeva, N., Zache, N., Shilov, A., Hultcrantz, M., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m501664200 · Cited by 247
Self-citation
Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73
Strano, S., Munarriz, E. R., Rossi, M., Cristofanelli, B., Shaul, Y., Castagnoli, L., Levine, A. J., Sacchi, A., Cesareni, G., Oren, M., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003360200 · Cited by 241
Analysis of the most representative tumour‐derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation.
Ory, K., Legros, Y., Auguin, C., & Soussi, T. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06656.x · Cited by 230
Hot-spot mutants of p53 core domain evince characteristic local structural changes
Wong, K., DeDecker, B. S., Freund, S. M. V., Proctor, M. R., Bycroft, M., & Fersht, A. R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8438 · Cited by 219
Conformational shifts propagate from the oligomerization domain of p53 to its tetrameric DNA binding domain and restore DNA binding to select p53 mutants.
Halazonetis, T. D., & Kandil, A. N. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb06199.x · Cited by 211
Treatment of Terminal Peritoneal Carcinomatosis by a Transducible p53-Activating Peptide
Snyder, E. L., Meade, B. R., Saenz, C. C., & Dowdy, S. F. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020036 · Cited by 206
p53 Linear Diffusion along DNA Requires Its C Terminus
McKinney, K. M., Mattia, M., Gottifredi, V., & Prives, C. L. (2004) · Molecular Cell · doi:10.1016/j.molcel.2004.09.032 · Cited by 194
Activation of the cryptic DNA binding function of mutant forms of p53
Hupp, T. R., Meek, D. W., Midgley, C., & Lane, D. P. (1993) · Nucleic Acids Research · doi:10.1093/nar/21.14.3167 · Cited by 190
Structure, Function, and Aggregation of the Zinc-Free Form of the p53 DNA Binding Domain
Butler, J. S., & Loh, S. N. (2003) · Biochemistry · doi:10.1021/bi026635n · Cited by 190
Characterization of the p53-rescue drug CP-31398 in vitro and in living cells
Rippin, T. M., Bykov, V. J. N., Freund, S. M. V., Selivanova, G., Wiman, K. G., & Fersht, A. R. (2002) · Oncogene · doi:10.1038/sj.onc.1205362 · Cited by 186
Self-citation
p53 gene mutation: software and database
Béroud, C. (1996) · Nucleic Acids Research · doi:10.1093/nar/24.1.147 · Cited by 185
Temporal dissection of p53 function in vitro and in vivo
Christophorou, M. A., Martı́n-Zanca, D., Soucek, L., Lawlor, E. R., Swigart, L. B., Verschuren, E. W., & Evan, G. I. (2005) · Nature Genetics · doi:10.1038/ng1572 · Cited by 184
Structures of p53 Cancer Mutants and Mechanism of Rescue by Second-site Suppressor Mutations
Joerger, A. C., Ang, H. C., Veprintsev, D. B., Blair, C. M., & Fersht, A. R. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m500179200 · Cited by 181
Inhibition of MDM2 by hsp90 Contributes to Mutant p53 Stabilization
Peng, Y., Chen, L., Li, C., Lu, W., & Chen, J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m102817200 · Cited by 180
Crystal Structure of a Superstable Mutant of Human p53 Core Domain
Joerger, A. C., Allen, M. D., & Fersht, A. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m309732200 · Cited by 178
Solution structure of p53 core domain: Structural basis for its instability
Cañadillas, J. M. P., Tidow, H., Freund, S. M. V., Rutherford, T. J., Ang, H. C., & Fersht, A. R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510941103 · Cited by 174
Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database
Bykov, V. J. N. (2002) · Carcinogenesis · doi:10.1093/carcin/23.12.2011 · Cited by 173
Mechanism of rescue of common p53 cancer mutations by second‐site suppressor mutations
Nikolova, P. V., Wong, K., DeDecker, B. S., Henckel, J., & Fersht, A. R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.3.370 · Cited by 173
Regulation of ES cell differentiation by functional and conformational modulation of p53
Sabapathy, K., Klemm, M., Jaenisch, R., & Wagner, E. F. (1997) · The EMBO Journal · doi:10.1093/emboj/16.20.6217 · Cited by 159
CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death
Wischhusen, J., Naumann, U., Ohgaki, H., Rastinejad, F., & Weller, M. (2003) · Oncogene · doi:10.1038/sj.onc.1207198 · Cited by 158
Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations
Brachmann, R. K., Yu, K., Eby, Y. J., Pavletich, N. P., & Boeke, J. D. (1998) · The EMBO Journal · doi:10.1093/emboj/17.7.1847 · Cited by 157
Hsp90 Chaperones Wild-type p53 Tumor Suppressor Protein
Walerych, D., Kudla, G., Gutkowska, M., Wawrzynów, B., Muller, L., King, F. W., Helwak, A., Boros, J., Żylicz, M., & Żylicz, M. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407601200 · Cited by 154
Efficient Specific DNA Binding by p53 Requires both Its Central and C-Terminal Domains as Revealed by Studies with High-Mobility Group 1 Protein
McKinney, K. M., & Prives, C. L. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.19.6797-6808.2002 · Cited by 149
p53 gene mutation: software and database
Béroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.200 · Cited by 149
Effects of Common Cancer Mutations on Stability and DNA Binding of Full-length p53 Compared with Isolated Core Domains
Ang, H. C., Joerger, A. C., Mayer, S., & Fersht, A. R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604209200 · Cited by 148
Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide
Issaeva, N., Friedler, A., Bozko, P. M., Wiman, K. G., Fersht, A. R., & Selivanova, G. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835733100 · Cited by 144
Self-citation
Stabilization of p53 by CP-31398 Inhibits Ubiquitination without Altering Phosphorylation at Serine 15 or 20 or MDM2 Binding
Wang, W., Takimoto, R., Rastinejad, F., & El‐Deiry, W. S. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.6.2171-2181.2003 · Cited by 144
Kinetic Instability of p53 Core Domain Mutants
Friedler, A., Veprintsev, D. B., Hansson, L. O., & Fersht, A. R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m302458200 · Cited by 140
Reactivation of Mutant p53 through Interaction of a C-Terminal Peptide with the Core Domain
Selivanova, G., Ryabchenko, L. G., Jansson, E. Å., Iotsova, V., & Wiman, K. G. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.5.3395 · Cited by 139
Self-citation
Strategies for therapeutic targeting of the p53 pathway in cancer
Wiman, K. G. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401921 · Cited by 135
Self-citation
The Mutant p53-Conformation Modifying Drug, CP-31398, Can Induce Apoptosis
Takimoto, R., Wang, W., Dicker, D. T., Rastinejad, F., Lyssikatos, J. P., & El‐Deiry, W. S. (2002) · Cancer Biology & Therapy · doi:10.4161/cbt.1.1.41 · Cited by 130
The structure of p53 tumour suppressor protein reveals the basis for its functional plasticity
Okorokov, A. L., Sherman, M. B., Plisson‐Chastang, C., Grinkevich, V. V., Sigmundsson, K., Selivanova, G., Milner, J., & Orlova, E. V. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601382 · Cited by 128
Self-citation
Therapeutic exploitation of the p53 pathway
Lane, D. P., & Laı́n, S. (2002) · Trends in Molecular Medicine · doi:10.1016/s1471-4914(02)02309-2 · Cited by 127
A temperature‐sensitive mutant of human p53.
Zhang, W., Guo, X. Y., Hu, G., Liu, W. B., Shay, J. W., & Deisseroth, A. B. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06543.x · Cited by 127
Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts
Wang, W., Kim, S.-H., & El‐Deiry, W. S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604507103 · Cited by 123
Small molecules that reactivate mutant p53
Bykov, V. J. N., Selivanova, G., & Wiman, K. G. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00454-4 · Cited by 123
Self-citation
Redox state of tumor suppressor p53 regulates its sequence-specific DNA binding in DNA-damaged cells by cysteine 277
Buzek, J. (2002) · Nucleic Acids Research · doi:10.1093/nar/30.11.2340 · Cited by 118
Conformational and Molecular Basis for Induction of Apoptosis by a p53 C-terminal Peptide in Human Cancer Cells
Kim, A. L., Raffo, A. J., Brandt‐Rauf, P. W., Pincus, M. R., Monaco, R. R., Abarzúa, P., & Fine, R. L. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.49.34924 · Cited by 114
Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay
Como, C. J. D., & Prives, C. L. (1998) · Oncogene · doi:10.1038/sj.onc.1202041 · Cited by 99
CRINEPT-TROSY NMR reveals p53 core domain bound in an unfolded form to the chaperone Hsp90
Rüdiger, S., Freund, S. M. V., Veprintsev, D. B., & Fersht, A. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132393699 · Cited by 97
Allosteric Regulation of the Thermostability and DNA Binding Activity of Human p53 by Specific Interacting Proteins
Hansen, S., Hupp, T. R., & Lane, D. P. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.7.3917 · Cited by 96
Addition of fresh medium induces cell cycle and conformation changes in p53, a tumour suppressor protein.
Milner, J., & Jv, W. (1990) · PubMed · Cited by 96
Isolation of Temperature-sensitive p53 Mutations from a Comprehensive Missense Mutation Library
Shiraishi, K., Kato, S., Han, S., Liu, W., Otsuka, K., Sakayori, M., Ishida, T., Takeda, M., Kanamaru, R., Ohuchi, N., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m310815200 · Cited by 95
Regulation of Mutant p53 Temperature-sensitive DNA Binding
Friedlander, P. A., Legros, Y., Soussi, T., & Prives, C. L. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.41.25468 · Cited by 94
Identification of an additional negative regulatory region for p53 sequence-specific DNA binding
Müller‐Tiemann, B., Halazonetis, T. D., & Elting, J. J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6079 · Cited by 89
Structure–based rescue of common tumor–derived p53 mutants
Wieczorek, A. M., Waterman, J. L. F., Waterman, M. J. F., & Halazonetis, T. D. (1996) · Nature Medicine · doi:10.1038/nm1096-1143 · Cited by 88
Microinjection of monoclonal antibody PAb421 into human SW480 colorectal carcinoma cells restores the transcription activation function to mutant p53.
Abarzúa, P., LoSardo, J. E., Gubler, M. L., & Neri, A. (1995) · PubMed · Cited by 83
Restoration of transcriptional activity of p53 mutants in human tumour cells by intracellular expression of anti-p53 single chain Fv fragments
de Fromentel, C. C., Gruel, N., Venot, C., Debüssche, L., Conseiller, E., Dureuil, C., Teillaud, J., Tocqué, B., & Bracco, L. P. (1999) · Oncogene · doi:10.1038/sj.onc.1202338 · Cited by 83
Restoration of wild‐type conformation and activity of a temperature‐sensitive mutant of p53 (p53V272M) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE‐1
North, S., Pluquet, O., Maurici, D., Ghissassi, F. E., & Hainaut, P. L. (2002) · Molecular Carcinogenesis · doi:10.1002/mc.10038 · Cited by 75
The p53 Stabilizing Compound CP-31398 Induces Apoptosis by Activating the Intrinsic Bax/Mitochondrial/Caspase-9 Pathway
Luu, Y., Bush, J., Cheung, K. J., & Li, G. (2002) · Experimental Cell Research · doi:10.1006/excr.2002.5526 · Cited by 74
Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein.
Vojtěšek, B., Dolezalova, H., Lauerová, L., Svitáková, M., Havlis, P., Kovařík, J., Midgley, C. A., & Lane, D. P. (1995) · PubMed · Cited by 72
Evidence for allosteric variants of wild-type p53, a tumour suppressor protein
Cook, A., & Milner, J. (1990) · British Journal of Cancer · doi:10.1038/bjc.1990.123 · Cited by 71
Restoration of the transcription activation function to mutant p53 in human cancer cells.
Abarzúa, P., LoSardo, J. E., Gubler, M. L., Spathis, R., Lu, Y., Felix, A. L., & Neri, A. (1996) · PubMed · Cited by 65
Reactivation of mutant p53: a new strategy for cancer therapy
Selivanova, G., Kawasaki, T., Ryabchenko, L. G., & Wiman, K. G. (1998) · Seminars in Cancer Biology · doi:10.1006/scbi.1998.0099 · Cited by 63
Self-citation
Effects of PRIMA‐1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion
Nahi, H., Lehmann, S., Möllgård, L., Bengtzén, S., Selivanova, G., Wiman, K. G., Paul, C., & Merup, M. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05210.x · Cited by 60
Self-citation
Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells
Rehman, A., Chahal, M. S., Tang, X., Bruce, J. E., Pommier, Y. G., & Daoud, S. S. (2005) · Breast Cancer Research · doi:10.1186/bcr1290 · Cited by 58
Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway
Li, Y., Mao, Y., Brandt-Rauf, P. W., Williams, A. C., & Fine, R. L. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0206 · Cited by 57
p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence.
Niewolik, D., Vojtěšek, B., & Kovařík, J. (1995) · PubMed · Cited by 55
The ‘wildtype’ conformation of p53: epitope mapping using hybrid proteins
Wang, P. L., Sait, F., & Winter, G. P. (2001) · Oncogene · doi:10.1038/sj.onc.1204316 · Cited by 47
Human p53 Phosphorylation Mimic, S392E, Increases Nonspecific DNA Affinity and Thermal Stability
Nichols, N. M., & Matthews, K. S. (2001) · Biochemistry · doi:10.1021/bi011736r · Cited by 43
The p53-Mdm2 Pathway: Targets for the Development of New Anticancer Therapeutics
Zheleva, D. I., Lane, D. P., & Fischer, P. M. (2003) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557033488178 · Cited by 42
Change of Conformation of the DNA-binding Domain of p53 Is the Only Key Element for Binding of and Interference with p73
Bensaad, K., Bras, M. L., Unsal, K., Strano, S., Blandino, G., Tominaga, O., Rouillard, D., & Soussi, T. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208233200 · Cited by 39
Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein
Liu, W.-L., Midgley, C., Stephen, C. W., Saville, M. K., & Lane, D. P. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.5082 · Cited by 38
Tumor-derived mutations within the DNA-binding domain of p53 that phenotypically resemble the deletion of the proline-rich domain
Roth, J. C., Koch, P., Contente, A., & Dobbelstein, M. (2000) · Oncogene · doi:10.1038/sj.onc.1203500 · Cited by 38
PRIMA-1MET induces nucleolar accumulation of mutant p53 and PML nuclear body-associated proteins
Rökaeus, N., Klein, G., Wiman, K. G., Székely, L., & Mattsson, K. (2006) · Oncogene · doi:10.1038/sj.onc.1209858 · Cited by 31
Self-citation
Activation of p53 by the cytoprotective aminothiol WR1065: DNA-damage-independent pathway and redox-dependent modulation of p53 DNA-binding activity
Pluquet, O., North, S., Richard, M., & Hainaut, P. L. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01655-6 · Cited by 27
Mutant p53: the loaded gun.
Selivanova, G. (2001) · PubMed · Cited by 27
Self-citation
ASPP2: A Gene that Controls Life and Death in Vivo
Vives, V., Slee, E. A., & Lü, X. (2006) · Cell Cycle · doi:10.4161/cc.5.19.3266 · Cited by 26
Biochemical characterization of different conformational states of the Sf9 cell‐purified p53His175 mutant protein
Cohen, P. A., Hupp, T. R., Lane, D. P., & Daniels, D. A. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)01603-8 · Cited by 13
Wild Type p53 Conformation, Structural Consequences of p53 Mutations and Mechanisms of Mutant p53 Rescue
Joerger, A. C., Friedler, A., & Fersht, A. R. (2007) · Springer eBooks · doi:10.1007/978-1-4020-2922-6_17 · Cited by 6
Functional Rescue of Mutant p53 as a Strategy to Combat Cancer
Selivanova, G., & Wiman, K. G. (2002) · Elsevier eBooks · doi:10.1016/b978-012476249-7/50021-7 · Cited by 3
Self-citation

Sorted by citations

The senescence-associated secretory phenotype: the dark side of tumor suppression
Coppé, J.-P., Desprez, P.-Y., Krtolica, A., & Campisi, J. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102144 · Cited by 5,206
Blinded by the Light: The Growing Complexity of p53
Vousden, K. H., & Prives, C. (2009) · Cell · doi:10.1016/j.cell.2009.04.037 · Cited by 3,163
Principles of cancer therapy: oncogene and non-oncogene addiction
Luo, J., Solimini, N. L., & Elledge, S. J. (2009) · Cell · doi:10.1016/j.cell.2009.02.024 · Cited by 1,765
Encyclopedia of Inorganic and Bioinorganic Chemistry
Casini, A., Miller, J. J., Gomes, L. M. F., & Storr, T. (2011) · Wiley eBooks · doi:10.1002/9781119951438 · Cited by 1,617
Principles of Protein−Protein Interactions: What are the Preferred Ways For Proteins To Interact?
Keskin, O., Gursoy, A., Ma, B., & Nussinov, R. (2008) · Chemical Reviews · doi:10.1021/cr040409x · Cited by 697

See all 186

Authors: Selivanova, G., & Wiman, K. G.
Affiliations: Karolinska Institutet (SE)
Corresponding author: Wiman, K G
ORCID: Selivanova, G
Wiman, K G
Venue: Oncogene
Publisher: Springer Science and Business Media LLC
Published: 2007-04-02
Volume: 26
Issue: 15
Pages: 2243-2254
ISSN: 0950-9232 (ISSN-L)
1476-5594
DOI: 10.1038/sj.onc.1210295
OpenAlex: W2025977492
Cited by: 186
References: 105
Citations by year: 2026: 1 · 2025: 4 · 2024: 3 · 2023: 7 · 2022: 6 · 2021: 9 · 2020: 8 · 2019: 6 · 2018: 9 · 2017: 7 · 2016: 16 · 2015: 11 · 2014: 9 · 2013: 11 · 2012: 7
FWCI: 1.98
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Oncogene (publishedVersion)
PubMed (publishedVersion)
Funders: Cancerfonden
Karolinska Institutet
Cancerföreningen i Stockholm
Topics: Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
Keywords: mutant p53, p53 reactivation, p53 tumor suppressor, missense mutations, protein unfolding, p53-dependent apoptosis, transcriptional activation, cancer therapy
MeSH terms: Humans, Mutation, Neoplasms, Protein Conformation, Tumor Suppressor Protein p53

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Reactivation of mutant p53: molecular mechanisms and therapeutic potential

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks